IBB News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IB

Volume

1.60M

Loading chart

IB

IBBiShares Biotechnology ETF

IBB

Pay with—

Available Balance0.00

IB

AUM

N/A

Volume

1.60M

Yield

0.02%

Chart Earnings News About Dividends Insider Filings

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?PBE is a smart beta ETF focused on biotechnology and genome companies with $412.99 million in assets. It has delivered strong year-to-date returns of 16.68% and one-year returns of 36.23%, but carries higher risk with a standard deviation of 20.18%. The fund charges a 0.59% expense ratio and holds concentrated positions in healthcare stocks like Natera, Illumina, and Biogen. Cheaper alternatives like XBI and IBB are available for investors seeking lower-cost options.Zacks Investment Research · Oct 14, 2026

Wednesday's Inflation Report Will Lock In Social Security's 2027 Cost-of-Living Adjustment (COLA). Here's the Number to Watch.The October 14 CPI report will determine Social Security's 2027 COLA, which is projected to be around 3.5% based on July and August CPI-W data. This would increase the average retired worker's monthly benefit from $2,088 to approximately $2,161, an increase of $73 per month. However, critics argue CPI-W doesn't fully capture retirees' actual inflation costs, particularly healthcare.The Motley Fool · Oct 13, 2026

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?The Invesco Biotechnology & Genome ETF (PBE) is a passively managed fund with $418.99 million in assets, offering exposure to the Healthcare-Biotech sector. With a 0.59% expense ratio and 1.38% dividend yield, it returned 18.51% over the past year but carries higher risk with a beta of 0.70 and 20.16% standard deviation. The fund holds 33 concentrated positions with top holdings including Royalty Pharma, Gilead Sciences, and Biogen. PBE received a Zacks ETF Rank of 3 (Hold), with larger competitors XBI and IBB offering lower expense ratios.Zacks Investment Research · Oct 13, 2026

Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH?The article compares two healthcare ETFs: IBB (biotech-focused) and IYH (broad healthcare). IBB has delivered stronger 1-year returns (38% vs 17.4%) but exhibits higher volatility and deeper drawdowns. IYH offers lower costs, higher dividend yield, and broader diversification, making it better for most long-term investors, while IBB suits those with conviction in biotech momentum who can tolerate volatility.The Motley Fool · Oct 11, 2026

Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBBThe article compares two healthcare ETFs: Vanguard Health Care ETF (VHT) offers broad sector exposure with a low 0.09% expense ratio and 1.4% dividend yield, while iShares Biotechnology ETF (IBB) focuses on biotech with higher growth potential (49.8% 1-year return) but greater volatility and a 39.8% maximum drawdown. VHT is recommended for conservative investors seeking stability, while IBB suits high-risk growth investors.The Motley Fool · Oct 5, 2026

Should You Invest in the VanEck Biotech ETF (BBH)?The VanEck Biotech ETF (BBH) offers low-cost exposure to the biotech sector with a 0.35% expense ratio and $462.7 million in assets. The fund tracks the MVIS US Listed Biotech 25 Index and holds 26 companies with top holdings including Amgen, Gilead Sciences, and Vertex Pharmaceuticals. BBH has returned 21.89% year-to-date and 39.46% over the past year, but carries higher risk with a beta of 0.70 and 19.89% standard deviation. The fund received a Zacks ETF Rank of 2 (Buy).Zacks Investment Research · Sep 16, 2026

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?The First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed fund offering broad exposure to the biotech sector with $2.91 billion in assets. The ETF has delivered strong performance with 29.36% gains year-to-date and 55.34% over the past year, though it carries higher risk with a beta of 0.66 and 20.71% standard deviation. With a 0.55% expense ratio and a Zacks ETF Rank of 2 (Buy), FBT is positioned as a solid option for biotech exposure, though larger competitors like IBB and XBI offer lower expense ratios.Zacks Investment Research · Sep 1, 2026

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?The article provides an in-depth analysis of the iShares Biotechnology ETF (IBB), a smart beta ETF with over $10.5 billion in assets that tracks the Nasdaq Biotechnology Index. With a 0.44% expense ratio and 252 holdings, IBB offers diversified exposure to biotechnology and pharmaceutical companies, though it carries higher risk with a beta of 0.70 and 20.59% standard deviation. The ETF returned 23.89% year-to-date and 51.48% over the past year as of August 2026, with top holdings including Amgen, Vertex Pharmaceuticals, and Gilead Sciences.Zacks Investment Research · Aug 31, 2026

Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?First Trust NYSE Arca Biotechnology Index Fund (FBT) and iShares Biotechnology ETF (IBB) offer different approaches to biotech sector exposure. FBT uses a concentrated 30-stock portfolio with higher returns (53.2% one-year, 168% ten-year) but greater risk, while IBB provides broader diversification with 248 holdings and lower fees (0.44% vs 0.55%). FBT has outperformed IBB over the past decade despite higher concentration risk.The Motley Fool · Jul 12, 2026

Stock Market Today: Nasdaq 100 Slips As Broadcom Plunges, Bitcoin Hits 4-Month LowsThe Nasdaq 100 fell 0.7% as chip stocks stumbled, with Broadcom cratering 15% despite beating earnings due to weak AI-chip revenue guidance. The Dow Jones rallied 1.7% on defensive and financial strength, while the S&P 500 remained flat. Bitcoin hit a 4-month low at $61,310. Other tech stocks like CrowdStrike, Ciena, and Five Below also declined despite beating estimates, reflecting a 'beat-and-bleed' market dynamic. Healthcare and financial stocks led gains.Benzinga · Jun 4, 2026

to start trading

IB

IBBiShares Biotechnology ETF

IBB

Pay with—

Available Balance0.00

Your PositionYou don't own any IBB yet.

Related Tickers

Earnings

Dividends

Last · Sep 15Quarterly

Amount$0.0110

Yield0.17%

Annual$0.34